Drugs / Phage
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06827041 | Feb 2024 → Feb 2025 overdue | periprosthetic joint infection | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04289948 | Mar 2019 → Jun 2022 | diabetes mellitus | University Hospitals of Derby and Burton NHS Foundation Trust | Withdrawn | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT05967130 | Jul 2023 → Jan 2024 | disease related to transplantation, urinary tract infection | Shahid Beheshti University of Medical Sciences | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-09-23 | Cytophage Technologies Inc. | Results Cytophage Reports Successful Results and Data from Second EU Pilot Study for AviPhage cytophage.com ↗
Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced positive results from its follow-up European pilot study of AviPhage, the Company’s proprietary poultry-based bacteriophage (phage) product for broiler chickens. |
| 2025-08-25 | Cytophage Technologies Inc. | Regulatory Cytophage secures Health Canada validation for OvaPhage and PhageFend products for use in food safety cytophage.com ↗
The LONO notifications are also a crucial step forward in granting phage products market access under a regulated path in Canada. |
| 2025-05-08 | Cytophage Technologies Inc. | Regulatory Cytophage Technologies Ltd. Secures Government of Canada New Substance Notification Approval to Facilitate Enterococcus Phage Therapy Trials cytophage.com ↗
Government of Canada Approval of Human Therapeutic Phage Enables a Critical First Step Towards Clinical Deployment and Creates Pathway to Multi-Phage Commercial Product |
| 2024-12-17 | Cytophage Technologies Inc. | Results Cytophage Technologies Reports Positive Outcome from Innovative Bacteriophage Therapy in Patient with Antibiotic-Resistant Infection cytophage.com ↗
Six months after receiving the treatment, the patient shows significant recovery, with fully-healed wounds, reduced inflammatory markers, and significantly improved functionality. |
All press releases naming this drug 15 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phage | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05967130 ↗ |
| Modality | Other / unclassified | “anti-staphylococcal phages” NCT04289948 ↗ |
| Route | Topical | “Phage gel will be applied to the index ulcer” NCT04289948 ↗ |